PRADAXA: payments to doctors
Payments that named PRADAXA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.4M
- Providers
- 7,889
- Transactions
- 23,475
- Average per transaction
- $60
The per-transaction average — $60 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,889 providers the average total is $179, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $999,218 | 70.7% |
| Boehringer Ingelheim International GmbH | $309,119 | 21.9% |
| Boehringer Ingelheim RCV GmbH & Co KG | $61,200 | 4.3% |
| Boehringer Ingelheim, Unipessoal, Lda. | $19,083 | 1.3% |
| Boehringer Ingelheim (phil.) Inc. | $14,640 | 1.0% |
| Boehringer Ingelheim Canada Ltd.ltee | $4,231 | 0.3% |
| Boehringer Ingelheim India Pvt. Ltd. | $2,360 | 0.2% |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | $1,740 | 0.1% |
| Nippon Boehringer Ingelheim Co., Ltd. | $1,500 | 0.1% |
| Boehringer Ingelheim MENA (scientific Office) Fz-llc | $1,000 | 0.1% |
| Boehringer Ingelheim Pharma GmbH & Co.kg | $215 | 0.0% |